Volume | 885,118 |
|
|||||
News | - | ||||||
Day High | 234.69 | Low High |
|||||
Day Low | 230.40 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Becton Dickinson and Company | BDX | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
233.91 | 230.40 | 234.69 | 230.48 | 233.83 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
20,809 | 885,118 | $ 231.40 | $ 204,815,880 | - | 229.395 - 287.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 139,606 | $ 230.48 | USD |
Becton Dickinson and Company Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
66.59B | 288.90M | - | 19.37B | 1.42B | 4.93 | 46.76 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Becton Dickinson News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 232.61 | 236.175 | 230.025 | 233.88 | 901,091 | -2.13 | -0.92% |
1 Month | 246.73 | 248.42 | 229.395 | 238.97 | 1,062,061 | -16.25 | -6.59% |
3 Months | 237.50 | 248.42 | 229.395 | 239.56 | 1,344,819 | -7.02 | -2.96% |
6 Months | 258.30 | 262.23 | 229.395 | 239.26 | 1,520,252 | -27.82 | -10.77% |
1 Year | 261.77 | 287.32 | 229.395 | 249.87 | 1,348,488 | -31.29 | -11.95% |
3 Years | 255.99 | 287.32 | 215.90 | 248.81 | 1,290,934 | -25.51 | -9.97% |
5 Years | 231.77 | 287.32 | 197.75 | 247.64 | 1,379,391 | -1.29 | -0.56% |
Becton Dickinson Description
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business. |